AC Immune Dividenden en inkoop

Dividend criteriumcontroles 0/6

AC Immune heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

-13.9%

Terugkoop Rendement

Totaal aandeelhoudersrendement	-13.9%
Toekomstig dividendrendement	n/a
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van ACIU in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van ACIU zijn gestegen.

Dividendrendement versus markt

AC Immune Dividendrendement versus markt

Hoe verhoudt ACIU dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (ACIU)	n/a
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.2%
Gemiddelde industrie (Biotechs)	2.3%
Analist prognose (ACIU) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividendrendement van ACIU kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van ACIU kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio ACIU te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat ACIU geen uitbetalingen heeft gerapporteerd.

AC Immune Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

New 90-day high: US$8.43

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: US$6.53

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely